Back to results

CompletedPhase 3

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

NCT00603239

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Birmingham, Alabama, United States

+24 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2008-01
Enrollment: 165 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (25)

Research SiteBirmingham, Alabama, United States
Research SiteConcord, California, United States
Research SiteFresno, California, United States
Research SiteDenver, Colorado, United States
Research SiteLas Vegas, Nevada, United States
Research SiteMogadore, Ohio, United States
Research SiteCorvallis, Oregon, United States
Research SiteNew Westminster, British Columbia, Canada
Research SiteWinnipeg, Manitoba, Canada
Research SiteAjax, Ontario, Canada
Research SiteCambridge, Ontario, Canada
Research SiteWindsor, Ontario, Canada
Research SiteChihuahua City, Chihuahua, Mexico
Research SiteCelaya, Guanajuato, Mexico
Research SiteMexico City, Mexico City, Mexico
Research SiteMonterrey, Nuevo León, Mexico
Research SiteMexico City, Mexico
Research SiteBaia Mare, Romania
Research SiteBrasov, Romania
Research SiteBucharest, Romania
Research SiteDolj, Romania
Research SiteIași, Romania
Research SiteSuceava, Romania
Research SiteJohannesburg, South Africa
Research SitePretoria, South Africa

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin — TrialFind